Ensign Peak Advisors
TXG icon

Ensign Peak Advisors’s 10x Genomics TXG Stock Holding History

Ensign Peak Advisors’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$289K Sell
7,540
-1,450
-16% -$38K ﹤0.01% 1197
2026
Q1 		$191K Hold
8,990
– – ﹤0.01% 1332
2025
Q4 		$147K Sell
8,990
-20,150
-69% -$304K ﹤0.01% 1441
2025
Q3 		$341K Hold
29,140
– – ﹤0.01% 1544
2025
Q2 		$337K Hold
29,140
– – ﹤0.01% 1637
2025
Q1 		$254K Hold
29,140
– – ﹤0.01% 1663
2024
Q4 		$418K Hold
29,140
– – ﹤0.01% 1643
2024
Q3 		$658K Hold
29,140
– – ﹤0.01% 1531
2024
Q2 		$567K Sell
29,140
-22,453
-44% -$588K ﹤0.01% 1568
2024
Q1 		$1.94M Buy
51,593
+14,716
+40% +$647K ﹤0.01% 944
2023
Q4 		$2.06M Buy
36,877
+148
+0.4% +$6.44K ﹤0.01% 902
2023
Q3 		$1.52M Sell
36,729
-18,028
-33% -$938K ﹤0.01% 934
2023
Q2 		$3.06M Buy
54,757
+21,129
+63% +$1.14M 0.01% 735
2023
Q1 		$1.88M Sell
33,628
-42,389
-56% -$1.98M ﹤0.01% 874
2022
Q4 		$2.77M Buy
76,017
+51,740
+213% +$1.69M 0.01% 716
2022
Q3 		$692K Sell
24,277
-19,677
-45% -$750K ﹤0.01% 1278
2022
Q2 		$1.99M Buy
43,954
+6,535
+17% +$339K ﹤0.01% 805
2022
Q1 		$2.85M Sell
37,419
-18,681
-33% -$1.63M 0.01% 752
2021
Q4 		$8.36M Buy
56,100
+18,800
+50% +$2.88M 0.02% 514
2021
Q3 		$5.43M Sell
37,300
-23,080
-38% -$3.96M 0.01% 626
2021
Q2 		$11.8M Buy
60,380
+6,766
+13% +$1.22M 0.02% 398
2021
Q1 		$9.71M Sell
53,614
-16,345
-23% -$2.82M 0.02% 425
2020
Q4 		$9.91M Sell
69,959
-20,961
-23% -$3.04M 0.02% 420
2020
Q3 		$11.3M Buy
90,920
+39,334
+76% +$4.13M 0.03% 421
2020
Q2 		$4.61M Sell
51,586
-8,886
-15% -$692K 0.01% 630
2020
Q1 		$3.77M Buy
60,472
+18,047
+43% +$1.41M 0.01% 597
2019
Q4 		$3.23M Buy
+42,425
New +$2.55M 0.01% 810

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ensign Peak Advisors's TXG Position: Q2 2026 in Review

Ensign Peak Advisors reduced its 10x Genomics (TXG) stake by 16% in Q2 2026, selling an estimated $38K and leaving 7,540 shares worth $289K. The position accounts for ﹤0.01% of the portfolio, ranked #1197.

Ensign Peak Advisors first reported a position in TXG in Q4 2019 and has held it in 27 quarters since. The position peaked at $11.8M in Q2 2021. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Ensign Peak Advisors held 7,540 shares of 10x Genomics worth $289K as of Q2 2026.
  • Ensign Peak Advisors sold 1,450 10x Genomics shares in Q2 2026, an estimated $38K.
  • 10x Genomics made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1197 holding.
  • Ensign Peak Advisors first reported a position in 10x Genomics in Q4 2019 and has held it in 27 quarters since.
  • Ensign Peak Advisors's 10x Genomics position peaked at $11.8M in Q2 2021.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.